miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

P&G Announces Fiscal Year 2026 Second Quarter Results

View original at finance.yahoo.com
P&G Announces Fiscal Year 2026 Second Quarter Results Net Sales +1%; Organic Sales 0% Diluted EPS $1.78, -5%; Core EPS $1.88, 0% UPDATES GAAP EPS FOR RESTRUCTURING OUTLOOK MAINTAINS FISCAL YEAR SALES, CORE EPS GROWTH AND CASH RETURN GUIDANCE CINCINNATI, January 22, 2026--(BUSINESS WIRE)--The Procter & Gamble Company (N…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • P&G's strategy is to reinvent P&G and create the CPG company of the future, delivering long-term balanced top- and bottom-line growth

    80% confidence

  • Commodity costs expected to be neutral for FY2026 (updated from prior forecast)

    80% confidence

  • Tariff costs expected to create $400M after-tax headwind for FY2026

    80% confidence

  • P&G's Q2 results keep the company on track to deliver within fiscal year guidance ranges for organic sales growth, core EPS growth and adjusted free cash flow productivity in a challenging consumer and geopolitical environment

    80% confidence

  • P&G has confidence in plans to deliver stronger results in the second half of fiscal year 2026

    80% confidence

  • FX expected to provide $200M after-tax tailwind for FY2026

    80% confidence

  • FY2026 organic sales growth guidance maintained at 0% to +4%

    80% confidence

  • FY2026 core EPS growth guidance maintained at 0% to +4% (range $6.83 to $7.09)

    80% confidence

  • FY2026 diluted EPS growth revised down to +1% to +6% (from +3% to +9%) due to restructuring charges

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
P&G Announces Fiscal Year 2026 Second Quarter Results — Source | Via News | es.VIA.NEWS